Opus Genetics’ (IRD) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Opus Genetics (NASDAQ:IRD) in a research note released on Wednesday,Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock.

Opus Genetics Stock Performance

NASDAQ:IRD opened at $1.09 on Wednesday. The firm has a market cap of $34.41 million, a PE ratio of -1.00 and a beta of 0.16. The business’s 50 day moving average price is $1.15. Opus Genetics has a 1-year low of $0.81 and a 1-year high of $2.65.

Insider Buying and Selling at Opus Genetics

In related news, CEO George Magrath acquired 100,000 shares of the company’s stock in a transaction on Thursday, December 26th. The stock was purchased at an average cost of $0.98 per share, with a total value of $98,000.00. Following the acquisition, the chief executive officer now directly owns 599,150 shares of the company’s stock, valued at approximately $587,167. The trade was a 20.03 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 6.60% of the company’s stock.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.